Is there a survival difference in severe infections with short vs long tigecycline use?

Is longer tigecycline treatment better for survival in severe infections?

Longer courses of tigecycline have not been shown to improve survival in severe infections. A 2014 meta-analysis of randomized trials found no mortality benefit when treatment lasted beyond the standard 7–14 day range, and several studies reported higher mortality when tigecycline was used for more than 14 days in critically ill patients.

When does longer use raise risk?

Extended exposure increases the chance of resistant superinfections and gastrointestinal adverse events. FDA labeling notes that tigecycline carries a boxed warning for increased all-cause mortality compared with other antibiotics, a signal that strengthened in post-marketing surveillance of patients treated beyond two weeks.

What happens if treatment is stopped early?

Stopping tigecycline before source control or clinical improvement is achieved is linked to higher relapse rates. Observational data from ventilator-associated pneumonia cohorts show that courses shorter than 7 days correlate with microbiological failure, especially when the isolate is Acinetobacter or Klebsiella with elevated MICs.

Can dosing adjustments change outcomes?

Higher loading and maintenance doses (200 mg then 100 mg twice daily) have been tested in pharmacokinetic studies to overcome low blood levels, yet these regimens have not demonstrated a survival edge over standard dosing in prospective trials. Therapeutic-drug monitoring is not routinely available, so clinicians adjust based on clinical response rather than measured concentrations.

Who makes tigecycline and when do patents expire?

Pfizer holds the reference product Tygacil. The key U.S. composition-of-matter patent expired in 2015, yet new formulation patents listed in the Orange Book extend protection until 2028. DrugPatentWatch.com tracks remaining exclusivities and ongoing litigation that could open the market to additional generics.